55 results about "Ω-3 fatty acids" patented technology

Recombinant expression of fat-1 gene of Caenorhabditis elegans in a wide variety of cells, including cells of Arabidopsis thaliana and Saccharomyces cerevisiae, produces a polypeptide having ω-3 desaturase activity.

A multiphase culturing process for high density heterotrophic microalgal growth uses crude glycerol as the primary carbon source and produces ω-3 fatty acids. The process uses multiphase growth conditions that decouple the phases of increasing cell density and increasing cell size and fatty acid production. The entire process is integrated with biodiesel production.

A dietary supplement system including three general components is provided. The first component is the fatty acid component and this includes sunflower seeds (containing omega 6 fatty acids), flax seed (containing omega 3 fatty acids) and powdered oils (containing omega 3 or omega 6 fatty acids and generally produced from sunflower oils). The weight ratio of omega 6 fatty acids to omega 3 fatty acids is 10:1 to 1:1, with 10:1 to 5:1 being preferred for normal animals and 2:1 to 1:1 being preferred for animals which have fatty acid responsive conditions. The second component is the GI component, which is used for facilitating animal gut health. This component includes prebiotics, probiotics and immunoglobulin (typically from albumin concentrate). The third component is the breed specific component and can include vitamins, minerals, additional fatty acids, antioxidants, amino acids, palatants, and nutraceutical additives.

The invention relates to the processing of substances that are not soluble, or soluble with difficulty, in water, in such a manner that, introduced into water or oil, these substances can yield a clear solution and can be easily integrated with finest homogeneous distribution into foodstuff, cosmetics, pharmaceuticals, and nutrient solutions. To achieve that, the invention provides a concentrate, consisting of an active substance from the group, which includes an algae oil, an essential oil, a terpene, phosphatidylserine, an ω 3 fatty acid, lanolin, a linoleic acid triglyceride, citral or tea tree oil, and a surplus amount of a polysorbate with at least two and half times the weight of the active substance.

The present invention can provide a nutrition composition useful for patients with renal diseases, which has an effective prophylactic or improving effect for various symptoms of malnutrition, inflammation, arteriosclerosis, abnormal lipid metabolism and oxidative stress, associated with renal diseases, or for diabetic nephropathy.

The nutrition composition of the present invention m contains one or more kinds of free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, and a lipid comprising ω-3 fatty acid and ω-6 fatty acid at a weight ratio (ω-6 fatty acid to ω-3 fatty acid) of 0.5-5.5. In addition, the composition further contains a soybean protein or a hydrolysate thereof together with the aforementioned lipid or instead of the aforementioned lipid.

The invention relates to a method for the production of multiply-unsaturated fatty acids in an organism, into which nucleic acids have been introduced, which code for polypeptides with Δ-5 elongase activity. Said nucleic acid sequences, optionally with further nucleic acid sequences, coding for polypeptides for the biosynthesis of fatty acids and lipid metabolism, are advantageously expressed in the organism. Nucleic acid sequences coding for a Δ-6 desaturase, a Δ-5 desaturase, Δ-4 desaturase and/or Δ-6 elongase activity are particularly advantageous and, advantageously, said saturases and elongases are derived from Thalassiosira, Euglena or Ostreococcus. The invention further relates to a method for the production of oils and/or triacylglycerides with an increased content of long-chain, multiply-unsaturated fatty acids. A particular embodiment of the invention is a method for the production of unsaturated ω-3 fatty acids and a method for the production of triglycerides with an increased content of unsaturated fatty acids, in particular, of Δ-3 fatty acids with more than three double bonds. Also disclosed is the production of a transgenic organism, preferably a transgenic plant, or a transgenic microorganism with increased content of ω-3 fatty acids, oils or lipids with ω-3 double bonds as a result of the expression of the elongases and desaturases employed in the above method, preferably in combination with ω-3 desaturases, for example a ω-3 desaturase from fungi of the family Pythiaceae such as the genus Phytophtora, for example, the genus and species Phytophtora infestans, or a ω-3 desaturase from algae such as the family Prasinophyceae, for example, the genus Ostreococcus and, particularly, the genus and species Ostreococcus tauri or diatomaceæ such as the genus Thalassiosira and, particularly, the genus and species Thalassiosira pseudonana. The invention also relates to the nucleic acid sequences, nucleic acid constructs, vectors and organisms containing the nucleic acid sequences and/or the nucleic acid constructs and transgenic organisms containing said nucleic acid sequences, nucleic acid constructs and/or vectors. A further part of the invention relates to oils, lipids and/or fatty acids produced according to the above method and use thereof and, furthermore, unsaturated fatty acids and triglycerides with an increased content of unsaturated fatty acids and use thereof.

This invention relates to compositions for delaying aging. The compositions comprise branched-chain amino acids and whey protein, and combinations thereof, containing the same, such as L-leucine, L-isoleucine, L-valine, lactoferrin, and β-lactoglobulin. The compositions are heat stable when dissolved in water at near neutral pH. The compositions are palatable and suitable for delivering orally administrable anti-aging agents such as ω-3 fatty acids, coenzyme Q₁₀, xanthophylls, L-arginine, and L-glutathione.

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm³. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

The invention relates to a compound and administration of the compound to mammals containing salsalate in a nanofied form to reduce inflammation. This compound and administration may be combined with caffeine, omega 3 fatty acids, sodium bicarbonate, and/or simvastatin to further benefit that administration.

The invention provides a halophytes omega 3 fatty acid desaturase gene and its expression vector and the said gene transformed cell and plant. The said gene expressed excessively in plants can increase the ª‡-linolenic acid content of leaf, can increase the cold-resistant, salt-tolerant and antimycotic ability, and can promote nutritious value of vegetable. That antisense suppression of the said gene expression in vivo plant can reduce ª‡-linolenic acid content, and can promote the plant high temperature resistance. The invention relates to chimeric gene construction with eukaryon expression promotor, and chimeric gene transformed host cell and recombination and transformation method. At same time, the invention provides a method for cultivating transgenic plant in which the gene is expressed excessively or antisense suppressed.

Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics.